

Correction

Baseline Frequency of Inflammatory Cxcl9-Expressing Tumor-Associated Macrophages Predicts Response to Avelumab Treatment

Yan Qu, Ji Wen, Graham Thomas, Wenjing Yang, Weiwei Prior, Wenqian He, Purnima Sundar, Xiao Wang, Shobha Potluri, and Shahram Salek-Ardakani*

*Correspondence: shahram.salek-ardakani@pfizer.com
<https://doi.org/10.1016/j.celrep.2020.108115>

(Cell Reports 32, 107873-1–107873-11.e1–e4; July 7, 2020)

In the originally published version of this paper, Figure 3A contained some incorrectly labeled dendritic cell populations. The figure has been updated, and the corrected figure now appears here and with the paper online.

The authors regret this error.






Figure 3. *Cxcl9*⁺ Monocyte-Derived TAMs Predict Responsiveness to Anti-PD-L1 Therapy (Corrected)




Figure 3. *Cxcl9*⁺ Monocyte-Derived TAMs Predict Responsiveness to Anti-PD-L1 Therapy (Original)